Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-16

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to assess the effect of a new PPARgamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. Based on their previous experimental results, the investigators hypothesized that modulating intestinal PPARgamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia

NCT01145586

Lactose Intolerance

COMPLETED PHASE3

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369

Celiac Disease

TERMINATED PHASE4

Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects

NCT01002261

Liver Cirrhosis

COMPLETED

Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy

NCT01113567

Hepatic Encephalopathy Liver Cirrhosis

TERMINATED NA

Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic

NCT04100109

Obesity, Adolescent Obesity, Childhood

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lactose Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lactase expression induction by GED

Group Type EXPERIMENTAL

GED

Intervention Type DRUG

Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GED

Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects undergoing gastroduodenal endoscopy for digestive cancer screening
* Subjects undergoing gastroduodenal endoscopy for ulcerative gastroduodenal diseases
* Subjects undergoing gastroduodenal endoscopy for epigastric pains
* Subjects undergoing gastroduodenal endoscopy for gastroesophageal reflux diseases

Exclusion Criteria

* Subjects with macroscopic duodenal lesions detected at endoscopy
* Subjects suffering from coeliac disease
* Subjects suffering from atrophic gastritis
* Subjects who use anticoagulant
* Pregnancy or breast feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes